MedPath

NANOCARRIER CO., LTD.

🇯🇵Japan
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

7

Active:0
Completed:5

Trial Phases

3 Phases

Phase 1:5
Phase 2:1
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 1
5 (71.4%)
Phase 2
1 (14.3%)
Phase 3
1 (14.3%)

Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen

Phase 2
Conditions
SCCHN
Interventions
First Posted Date
2018-12-11
Last Posted Date
2021-03-17
Lead Sponsor
NanoCarrier Co., Ltd.
Target Recruit Count
136
Registration Number
NCT03771820
Locations
🇭🇷

0603, Osijek, Croatia

🇭🇷

0601, Zagreb, Croatia

🇭🇷

0602, Zagreb, Croatia

and more 20 locations

Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma

Phase 1
Conditions
Metastatic Sarcoma
Solid Tumor
Soft Tissue Sarcoma
Sarcoma
Interventions
First Posted Date
2017-05-30
Last Posted Date
2020-02-28
Lead Sponsor
NanoCarrier Co., Ltd.
Target Recruit Count
150
Registration Number
NCT03168061
Locations
🇺🇸

City of Hope National Medical Center, Duarte, California, United States

🇺🇸

University of California Los Angeles, Santa Monica, California, United States

🇺🇸

Sarcoma Oncology Research Center, LLC., Santa Monica, California, United States

and more 4 locations

Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma

Phase 1
Completed
Conditions
Advanced Cancer
Lymphoma
Interventions
First Posted Date
2017-05-30
Last Posted Date
2018-02-23
Lead Sponsor
NanoCarrier Co., Ltd.
Target Recruit Count
34
Registration Number
NCT03168035
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 1
Completed
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
First Posted Date
2017-04-12
Last Posted Date
2019-04-29
Lead Sponsor
NanoCarrier Co., Ltd.
Target Recruit Count
1
Registration Number
NCT03109158
Locations
🇺🇸

Cedars Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

🇺🇸

Northwestern University, Chicago, Illinois, United States

and more 17 locations

Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer

Phase 1
Completed
Conditions
Solid Tumors
Interventions
First Posted Date
2014-09-15
Last Posted Date
2025-01-22
Lead Sponsor
NanoCarrier Co., Ltd.
Target Recruit Count
119
Registration Number
NCT02240238
Locations
🇺🇸

California Cancer Associates for Research and Excellence, Encinitas, California, United States

🇺🇸

UC San Diego Moores Cancer Center, La Jolla, California, United States

🇺🇸

Pacific Hematology Oncology Associates, San Francisco, California, United States

and more 19 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.